Immutep Advances IMP761 in Promising Phase I Trial
Company Announcements

Immutep Advances IMP761 in Promising Phase I Trial

Immutep Ltd (AU:IMM) has released an update.

Immutep Ltd has announced that its Phase I study of IMP761, a novel LAG-3 immunotherapy, has progressed to the dose escalation stage after successful initial trials with no safety issues. This advancement marks a significant step for the biotechnology company in its efforts to develop treatments for cancer and autoimmune diseases. Investors and market watchers are keenly awaiting the safety data expected by the end of the year, which could influence the company’s market position.

For further insights into AU:IMM stock, check out TipRanks’ Stock Analysis page.

Related Articles
TheFlyImmutep reports Q1 cash receipts from custmers $20,000
TipRanks Australian Auto-Generated NewsdeskImmutep Ltd Reports Positive Advances in Cancer Trials
TipRanks Australian Auto-Generated NewsdeskImmutep Limited Announces 2024 AGM Details
Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App